Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 6 November 1998:
Vol. 282. no. 5391, pp. 1072 - 1074
DOI: 10.1126/science.282.5391.1072
Prev | Table of Contents | Next

Viewpoint

Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs

Ira Shoulson

The experimental therapeutics of neurodegenerative disorders is in its infancy, but neuroprotective strategies are already being applied in healthy persons at high risk of developing disease as well as in patients with manifest illness. Knowledge of etiology and pathogenesis, improved design of clinical trials, the development of biological markers, the advent of genetic animal models, the enhanced identification of susceptibility factors, and more effective drug delivery--such advances have improved the prospects for forestalling onset of illness and clinical decline in the growing numbers of people affected by neurodegenerative disorders.

The author is in the Department of Neurology, University of Rochester Medical Center, School of Medicine and Dentistry, Suite 212, 1351 Mt. Hope Avenue, Rochester, NY 14620, USA.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Potential for Estrogens in Preventing Alzheimer's Disease..
J. W. Simpkins, E. Perez, Xiaofei Wang, ShaoHua Yang, Yi Wen, and M. Singh (2009)
Therapeutic Advances in Neurological Disorders 2, 31-49
   Abstract »    PDF »
Optimized, Automated Striatal Uptake Analysis Applied to SPECT Brain Scans of Parkinson's Disease Patients.
I. G. Zubal, M. Early, O. Yuan, D. Jennings, K. Marek, and J. P. Seibyl (2007)
J. Nucl. Med. 48, 857-864
   Abstract »    Full Text »    PDF »
Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.
J.C.H. van Oostrom, R. P. Maguire, C. C. Verschuuren-Bemelmans, L. Veenma-van der Duin, J. Pruim, R. A.C. Roos, and K. L. Leenders (2005)
Neurology 65, 941-943
   Abstract »    Full Text »    PDF »
Dementia with Lewy Bodies: Molecular Pathogenesis and Implications for Classification.
J. L. Cummings (2004)
J Geriatr Psychiatry Neurol 17, 112-119
   Abstract »    PDF »
Imaging the dopamine system to assess disease-modifying drugs: Studies comparing dopamine agonists and levodopa.
K. Marek, D. Jennings, and J. Seibyl (2003)
Neurology 61, S43-48
   Full Text »
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression.
Parkinson Study Group (2002)
JAMA 287, 1653-1661
   Abstract »    Full Text »    PDF »
[123I]{beta}-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.
K. Marek, R. Innis, C. van Dyck, B. Fussell, M. Early;, S. Eberly, D. Oakes, and J. Seibyl (2001)
Neurology 57, 2089-2094
   Abstract »    Full Text »    PDF »
Of mice and men: A model of HIV encephalitis.
J. C. McArthur and K. Kieburtz (2000)
Neurology 54, 284
   Full Text »    PDF »
Neuronal Death and Blood-Brain Barrier Breakdown after Excitotoxic Injury Are Independent Processes.
Z.-l. Chen, J. A. Indyk, T. H. Bugge, K. W. Kombrinck, J. L. Degen, and S. Strickland (1999)
J. Neurosci. 19, 9813-9820
   Abstract »    Full Text »    PDF »
PDZ Domain-dependent Suppression of NF-kappa B/p65-induced Abeta 42 Production by a Neuron-specific X11-like Protein.
S. Tomita, T. Fujita, Y. Kirino, and T. Suzuki (2000)
J. Biol. Chem. 275, 13056-13060
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)